Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

Cancer Immunology Research - Tập 6 Số 5 - Trang 605-616 - 2018
Anna Wing1, Carlos Alberto Fajardo2, Avery D. Posey1, Carolyn E. Shaw1, Tong Da1, Regina M. Young1, Ramón Alemany2, Carl H. June1, Sònia Guedan1
11Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
22ProCure Program, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona.

Tóm tắt

Abstract T cells expressing chimeric antigen receptors (CART) have shown significant promise in clinical trials to treat hematologic malignancies, but their efficacy in solid tumors has been limited. Oncolytic viruses have the potential to act in synergy with immunotherapies due to their immunogenic oncolytic properties and the opportunity of incorporating therapeutic transgenes in their genomes. Here, we hypothesized that an oncolytic adenovirus armed with an EGFR-targeting, bispecific T-cell engager (OAd-BiTE) would improve the outcome of CART-cell therapy in solid tumors. We report that CART cells targeting the folate receptor alpha (FR-α) successfully infiltrated preestablished xenograft tumors but failed to induce complete responses, presumably due to the presence of antigen-negative cancer cells. We demonstrated that OAd-BiTE–mediated oncolysis significantly improved CART-cell activation and proliferation, while increasing cytokine production and cytotoxicity, and showed an in vitro favorable safety profile compared with EGFR-targeting CARTs. BiTEs secreted from infected cells redirected CART cells toward EGFR in the absence of FR-α, thereby addressing tumor heterogeneity. BiTE secretion also redirected CAR-negative, nonspecific T cells found in CART-cell preparations toward tumor cells. The combinatorial approach improved antitumor efficacy and prolonged survival in mouse models of cancer when compared with the monotherapies, and this was the result of an increased BiTE-mediated T-cell activation in tumors. Overall, these results demonstrated that the combination of a BiTE-expressing oncolytic virus with adoptive CART-cell therapy overcomes key limitations of CART cells and BiTEs as monotherapies in solid tumors and encourage its further evaluation in human trials. Cancer Immunol Res; 6(5); 605–16. ©2018 AACR.

Từ khóa


Tài liệu tham khảo

Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930

Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Gilham, 2012, CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe, Trends Mol Med, 18, 378, 10.1016/j.molmed.2012.04.009

Gajewski, 2013, Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment, Curr Opin Immunol, 25, 268, 10.1016/j.coi.2013.02.009

Anderson, 2017, Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies, Cancer Cell, 31, 311, 10.1016/j.ccell.2017.02.008

Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, 29, 235, 10.1146/annurev-immunol-031210-101324

Lavin, 2017, Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses, Cell, 169, 750, 10.1016/j.cell.2017.04.014

Chevrier, 2017, An immune atlas of clear cell renal cell carcinoma, Cell, 169, 736, 10.1016/j.cell.2017.04.016

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792

Baitsch, 2011, Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients, J Clin Invest, 121, 2350, 10.1172/JCI46102

Crespo, 2013, T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Curr Opin Immunol, 25, 214, 10.1016/j.coi.2012.12.003

Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin Cancer Res, 20, 4262, 10.1158/1078-0432.CCR-13-2627

Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020

Burrell, 2013, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, 501, 338, 10.1038/nature12625

McGranahan, 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, 27, 15, 10.1016/j.ccell.2014.12.001

O'Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9

Dunn, 2004, The three Es of cancer immunoediting, Annu Rev Immunol, 22, 329, 10.1146/annurev.immunol.22.012703.104803

Russell, 2012, Oncolytic virotherapy, Nat Biotechnol, 30, 658, 10.1038/nbt.2287

Keller, 2016, Oncolytic viruses—immunotherapeutics on the rise, J Mol Med, 94, 979, 10.1007/s00109-016-1453-9

Guedan, 2010, Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth, Mol Ther, 18, 1275, 10.1038/mt.2010.79

Guedan, 2011, GALV expression enhances the therapeutic efficacy of anoncolytic adenovirus by inducing cell fusion and enhancingvirus distribution, Gene Ther, 19, 1048, 10.1038/gt.2011.184

Fajardo, 2017, Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy, Cancer Res, 77, 2052, 10.1158/0008-5472.CAN-16-1708

Cody, 2009, Armed replicating adenoviruses for cancer virotherapy, Cancer Gene Ther, 16, 473, 10.1038/cgt.2009.3

Klinger, 2016, Harnessing T cells to fight cancer with BiTE® antibody constructs–past developments and future directions, Immunol Rev, 270, 193, 10.1111/imr.12393

Klinger, 2012, Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab, Blood, 119, 6226, 10.1182/blood-2012-01-400515

Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci, 106, 3360, 10.1073/pnas.0813101106

Barrett, 2013, Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia, Hum Gene Ther, 24, 717, 10.1089/hum.2013.075

Guedan, 2014, ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells, Blood, 124, 1070, 10.1182/blood-2013-10-535245

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol Ther, 17, 1453, 10.1038/mt.2009.83

Rojas, 2011, Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD, Gene Ther, 19, 453, 10.1038/gt.2011.106

Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J Clin Invest, 126, 3814, 10.1172/JCI87366

Hegde, 2016, Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape, J Clin Invest, 126, 3036, 10.1172/JCI83416

Hegde, 2013, Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma, Mol Ther, 21, 2087, 10.1038/mt.2013.185

Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing Erbb2, Mol Ther, 18, 843, 10.1038/mt.2010.24

Liu, 2015, Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice, Cancer Res, 75, 3596, 10.1158/0008-5472.CAN-15-0159

Johnson, 2015, Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci Transl Med, 7, 275ra22, 10.1126/scitranslmed.aaa4963

Wang, 2015, Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors, Cancer Immunol Res, 3, 815, 10.1158/2326-6066.CIR-15-0054

Fry, 2017, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441

Hinrichs, 2013, Reassessing target antigens for adoptive T-cell therapy, Nat Biotechnol, 31, 999, 10.1038/nbt.2725

Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109, 10.1016/j.cell.2017.08.027

Nishio, 2014, Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors, Cancer Res, 74, 5195, 10.1158/0008-5472.CAN-14-0697

Tanoue, 2017, Armed oncolytic adenovirus–expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors, Cancer Res, 77, 2040, 10.1158/0008-5472.CAN-16-1577

Thông tin
Thông tin xuất bản

Cancer Immunology Research

Tập 6 Số 5

605-616

Thông tin tác giả